Top

BMC Medical Informatics and Decision Making

Published in:

Open Access 01-12-2019 | Research Article

Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports

Authors: Ruoqi Liu, Ping Zhang

Published in: BMC Medical Informatics and Decision Making | Issue 1/2019

Abstract

Background

Adverse drug reaction (ADR) is a major burden for patients and healthcare industry. Early and accurate detection of potential ADRs can help to improve drug safety and reduce financial costs. Post-market spontaneous reports of ADRs remain a cornerstone of pharmacovigilance and a series of drug safety signal detection methods play an important role in providing drug safety insights. However, existing methods require sufficient case reports to generate signals, limiting their usages for newly approved drugs with few (or even no) reports.

Methods

In this study, we propose a label propagation framework to enhance drug safety signals by combining drug chemical structures with FDA Adverse Event Reporting System (FAERS). First, we compute original drug safety signals via common signal detection algorithms. Then, we construct a drug similarity network based on chemical structures. Finally, we generate enhanced drug safety signals by propagating original signals on the drug similarity network. Our proposed framework enriches post-market safety reports with pre-clinical drug similarity network, effectively alleviating issues of insufficient cases for newly approved drugs.

Results

We apply the label propagation framework to four popular signal detection algorithms (PRR, ROR, MGPS, BCPNN) and find that our proposed framework generates more accurate drug safety signals than the corresponding baselines. In addition, our framework identifies potential ADRs for newly approved drugs, thus paving the way for early detection of ADRs.

Conclusions

The proposed label propagation framework combines pre-clinical drug structures with post-market safety reports, generates enhanced drug safety signals, and can potentially help to accurately detect ADRs ahead of time.

Availability

The source code for this paper is available at: https://github.com/ruoqi-liu/LP-SDA.

Available only for authorised users

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000; 356(9237):1255–9.CrossRef

Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998; 279(15):1200–5.CrossRef

Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y. When good drugs go bad. Nature. 2007; 446(7139):975.CrossRef

Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the fda adverse event reporting system. Clin Pharmacol Ther. 2013; 93(6):539–46.CrossRef

Harpaz R, Vilar S, DuMouchel W, Salmasian H, Haerian K, Shah NH, Chase HS, Friedman C. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2012; 20(3):413–9.CrossRef

Li Y, Ryan PB, Wei Y, Friedman C. A method to combine signals from spontaneous reporting systems and observational healthcare data to detect adverse drug reactions. Drug Saf. 2015; 38(10):895–908.CrossRef

Leaman R, Wojtulewicz L, Sullivan R, Skariah A, Yang J, Gonzalez G. Towards internet-age pharmacovigilance: extracting adverse drug reactions from user posts to health-related social networks. In: Proceedings of the 2010 Workshop on Biomedical Natural Language Processing. Association for Computational Linguistics: 2010. p. 117–125.

Nikfarjam A, Sarker A, O’connor K, Ginn R., Gonzalez G.Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. J Am Med Inform Assoc. 2015; 22(3):671–81.PubMedPubMedCentral

Evans S, Waller PC, Davis S. Use of proportional reporting ratios (prrs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001; 10(6):483–6.CrossRef

10.

Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004; 13(8):519–23.CrossRef

11.

Waller P, Van Puijenbroek E, Egberts A, Evans S. The reporting odds ratio versus the proportional reporting ratio:’deuce’. Pharmacoepidemiol Drug Saf. 2004; 13(8):525–6.CrossRef

12.

DuMouchel W. Bayesian data mining in large frequency tables, with an application to the fda spontaneous reporting system. Am Stat. 1999; 53(3):177–90.

13.

Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998; 54(4):315–21.CrossRef

14.

Vilar S, Harpaz R, Chase HS, Costanzi S, Rabadan R, Friedman C. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J Am Med Inform Assoc. 2011; 18(Supplement_1):73–80.CrossRef

15.

Vilar S, Harpaz R, Santana L, Uriarte E, Friedman C. Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PloS One. 2012; 7(7):41471.CrossRef

16.

Vilar S, Ryan P, Madigan D, Stang P, Schuemie M, Friedman C, Tatonetti N, Hripcsak G. Similarity-based modeling applied to signal detection in pharmacovigilance. CPT: Pharmacometrics Syst Pharmacol. 2014; 3(9):1–9.

17.

Vilar S, Tatonetti NP, Hripcsak G. 3d pharmacophoric similarity improves multi adverse drug event identification in pharmacovigilance. Sci Rep. 2015; 5:8809.CrossRef

18.

Fliri AF, Loging WT, Thadeio PF, Volkmann RA. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat Chem Biol. 2005; 1(7):389.CrossRef

19.

Atias N, Sharan R. An algorithmic framework for predicting side effects of drugs. J Comput Biol. 2011; 18(3):207–218.CrossRef

20.

Pauwels E, Stoven V, Yamanishi Y. Predicting drug side-effect profiles: a chemical fragment-based approach. BMC bioinformatics. 2011; 12(1):169.CrossRef

21.

Liu M, Wu Y, Chen Y, Sun J, Zhao Z, Chen X-w, Matheny ME, Xu H. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J Am Med Inform Assoc. 2012; 19(e1):28–35.CrossRef

22.

Zhang W, Yue X, Liu F, Chen Y, Tu S, Zhang X. A unified frame of predicting side effects of drugs by using linear neighborhood similarity. BMC Syst Biol. 2017; 11(6):101.CrossRef

23.

Dey S, Luo H, Fokoue A, Hu J, Zhang P. Predicting adverse drug reactions through interpretable deep learning framework. BMC Bioinformatics. 2018; 19(21):476.CrossRef

24.

Luo H, Fokoue-Nkoutche A, Singh N, Yang L, Hu J, Zhang P. Molecular docking for prediction and interpretation of adverse drug reactions. Comb Chem High Throughput Screen. 2018; 21(5):314–22.CrossRef

25.

FDA’s Adverse Event Reporting System (FAERS). https://open.fda.gov/data/faers/. Accessed 30 June 2019.

26.

Banda J, Evans L, Vanguri R, Tatonetti N, Ryan P, Shah N. Data from: A curated and standardized adverse drug event resource to accelerate drug safety research. Dryad Digital Repository. 2016. https://doi.org/10.5061/dryad.8q0s4.

27.

Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (meddra). Drug Saf. 1999; 20(2):109–17.CrossRef

28.

Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Han L, He J, He S, Shoemaker BA, et al.Pubchem substance and compound databases. Nucleic Acids Res. 2015; 44(D1):1202–13.CrossRef

29.

Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol. 2010; 6(1):343.CrossRef

30.

Tatonetti NP, Patrick PY, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Trans Med. 2012; 4(125):125–3112531.CrossRef

31.

Szarfman A, Machado SG, O’neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the us fd’s spontaneous reports database. Drug Saf. 2002; 25(6):381–92.CrossRef

32.

PubChem Substructure Fingerprint V1.3. ftp://ftp.ncbi.nlm.nih.gov/ pubchem/specifications/pubchem_fingerprints.txt. Accessed 30 June 2019.

33.

Zhou D, Bousquet O, Lal TN, Weston J, Schölkopf B. Learning with local and global consistency. In: Advances in Neural Information Processing Systems: 2004. p. 321–328.

34.

Zhang W, Yue X, Huang F, Liu R, Chen Y, Ruan C. Predicting drug-disease associations and their therapeutic function based on the drug-disease association bipartite network. Methods. 2018; 145:51–59.CrossRef

35.

Designated Medical Event (DNE). https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/signal-management. Accessed 30 June 2019.

36.

Liraglutide: Monograph for Professionals. https://www.drugs.com/monograph/liraglutide.html. Accessed 30 June 2019.

37.

Liraglutide: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overviewprocess&ApplNo=022341. Accessed 30 June 2019.

38.

Liraglutide: European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/victoza. Accessed 30 June 2019.

39.

Liraglutide: FDA Approved Drug Products Safety Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022341s004lbl.pdf. Accessed 30 June 2019.

40.

Pazopanib: Uses, Side Effects and Warnings. https://www.drugs.com/mtm/pazopanib.html. Accessed 30 June 2019.

41.

Pazopanib: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022465. Accessed 30 June 2019.

42.

Pazopanib: European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/votrient. Accessed 30 June 2019.

43.

Pazopanib: FDA Approved Drug Products Safety Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022465s018lbl.pdf. Accessed 30 June 2019.

Title: Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports
Authors: Ruoqi Liu
Ping Zhang
Publication date: 01-12-2019
Publisher: BioMed Central
Published in: BMC Medical Informatics and Decision Making / Issue 1/2019
Electronic ISSN: 1472-6947
DOI: https://doi.org/10.1186/s12911-019-0999-1

ACC 2024 Congress

Springer Medicine

Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports

Abstract

Background

Methods

Results

Conclusions

Availability

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Availability

Please log in to get access to this content

Other articles of this Issue 1/2019

Exploring the role of competing demands and routines during the implementation of a self-management tool for type 2 diabetes: a theory-based qualitative interview study

Effectiveness of a decision aid for promoting colorectal cancer screening in Spain: a randomized trial

The effect of self-management education through weblogs on the quality of life of diabetic patients

ThalPred: a web-based prediction tool for discriminating thalassemia trait and iron deficiency anemia

Responsible data sharing in a big data-driven translational research platform: lessons learned

Selection process for botulinum toxin injections in patients with chronic-stage hemiplegic stroke: a qualitative study